Rallybio Corporation
RLYB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.08 | 0.05 | 0.25 |
| FCF Yield | -29.13% | -55.28% | -34.82% | -23.00% |
| EV / EBITDA | -0.59 | -0.58 | -1.52 | -2.52 |
| Quality | ||||
| ROIC | -10.95% | -21.85% | -17.84% | -18.72% |
| Gross Margin | 100.00% | 100.00% | 100.00% | 21.05% |
| Cash Conversion Ratio | -0.41 | 0.86 | 1.08 | 0.89 |
| Growth | ||||
| Revenue 3-Year CAGR | 876,671.92% | 912,880.61% | 946,424.70% | 859,874.76% |
| Free Cash Flow Growth | 21.83% | 17.89% | -3.48% | 27.19% |
| Safety | ||||
| Net Debt / EBITDA | -1.99 | 0.94 | 1.52 | 1.19 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -834.00 |